Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 43

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 43
---
 Combination? A:NorthView Common Stock, NorthView Rights and NorthView Warrants are currently quoted on OTC Pink under the symbols NVAC, NVACR and NVACW, respectively.Upon consummation of the Business Combination, NorthView will continue to have one class of common stock which will be listed on Nasdaq under the symbol “PFSA”, and its warrants will be listed on Nasdaq under the symbol “PFSAW”. NorthView Rights will be converted into New Profusa Common Stock at the Closing. NorthView warrant holders and those stockholders who do not elect to have their shares of NorthView Common Stock redeemed for a pro rata share of the trust account need not submit their common stock or warrant certificates, and such shares of stock and warrants will remain outstanding. Q:Why is NorthView proposing the Business Combination? A:NorthView was organized to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses or entities. On December 22, 2021, NorthView completed its initial public offering of units, with each unit consisting of one share of NorthView Common Stock, one NorthView Right, and one -halfof one NorthView Warrant. Each NorthView Right entitles the holder thereof to receive one -tenthof one share of NorthView Common Stock, and each whole NorthView Warrant entitles the holder thereof to purchase one share of NorthView Common Stock at a price of $11.50, raising total gross proceeds of $189,750,000, reflecting the exercise in full of the underwriters’ over -allotmentoption. Since NorthView’s IPO, NorthView’s activity has been limited to the evaluation of business combination candidates. Profusa, Inc. is a digital health technology company based in Berkeley, CA, that has developed a real time, consumer -friendlyplatform which measures an individual’s biochemistry, is easy to use, cost -effective, and provides the necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. Based on its investigations of Profusa and the industry in which it operates, including the financial and other information provided by Profusa in the course of their negotiations in connection with the Merger Agreement, NorthView believes that the Business Combination with Profusa is advisable and in the best interests of NorthView and its stockholders. See “ Proposal 1 — The Business Combination — The NorthView Board’s Reasons for